Skip to main content

Vitekta FDA Approval History

FDA Approved: Yes (Discontinued) (First approved September 24, 2014)
Brand name: Vitekta
Generic name: elvitegravir
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Marketing Status: Discontinued

Vitekta (elvitegravir) is an integrase inhibitor for the combination treatment of HIV-1 infection in treatment-experienced adults.

Development timeline for Vitekta

DateArticle
Sep 25, 2014Approval FDA Approves Vitekta (elvitegravir) for HIV-1 Infection
Apr 21, 2014Gilead Sciences’ New Drug Application for Elvitegravir for HIV Therapy Accepted by U.S. FDA
Apr 29, 2013Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Jun 27, 2012Gilead Submits New Drug Application to U.S. FDA for HIV Integrase Inhibitor Elvitegravir for Treatment-Experienced Patients

See also

Vitekta (elvitegravir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer